What a fantastic #ASCO18! Congrats to Eric J. Small, MD, FASCO @YoungStrongDFCI Clifford Hudis & ASCO organizers on great conference. Wonderful to see so many friends, colleagues, patients, advocates, mentors. Feeling energized & inspired by all - looking forward to our continued work together

A particular highlight for me this year was the privilege of watching the successes of the junior investigators in my lab. Could not be more proud. Congrats Ada, Seth, Romualdo, Esha, Ofir, Ana! Wagle Lab #ASCO18

Thank you so much Nikhil Wagle, MD (he/him) for your mentorship and congrats to all my #labmates Wagle Lab Dana-Farber #Immunotherapy #mbc x.com/nikhilwagle/st…

#ASCO18 lab dinner @duckduckgoatchi (Forgot to get a pic of the whole crew!)

Quick recap of Ofir Cohen’s presentation “Acquired activating mutations in RTKs confer endocrine resistance in ER+ metastatic breast cancer through ER-reprogramming, MAPK signaling, and an induced stem-like cell state” in #SABCS19 General Session 2 earlier today

Over the past several yrs, we‘ve had a program to collect & deeply characterize metastatic biopsies from Dana-Farber patients with MBC (working w Nancy Lin, Eric Winer, MD, DFCI breast oncology colleagues, DFCI/BWH Center for Cancer Precision Med, & many others) #SABCS19

Over 4 years, we collected 500+ metastatic biopsies from 446 patients w MBC. Characterization includes whole exome sequencing (~20,000 genes), RNA-seq, and other genomic and molecular tests #SABCS19

Role of AKT mutations in mediating resistance to endocrine therapy and CDK 4/6i in MBC. Nice work led by Dr. Seth Wander ⁦Mass General Cancer Center⁩ and collaboration with ⁦Nikhil Wagle, MD (he/him)⁩. Implications for treatment in post CDK 4/6 setting.

Our annual lab holiday party, celebrating the end of a great and productive year. I am so lucky and grateful to have this incredible group of people to work with. Happy holidays! Wagle Lab Count Me In

Watching the #AACR21 session on sequencing metastatic #breastcancer? ICYMI in Cancer Discovery: The genomic landscape of intrinsic and acquired resistance to CDK4/6 inhibitors in patients with HR+ metastatic #BreastCancer Nikhil Wagle, MD (he/him) Dana-Farber Broad Institute cancerdiscovery.aacrjournals.org/content/10/8/1…

At #ASCO21 today–need to bring #clinicaltrials closer to patients to encourage participation & promote integration of molecular data, especially relevant for rare cancers. Here's a great case of patient-partnership to accelerate research in angiosarcoma nature.com/articles/s4159…

The Metastatic Breast Cancer Project (@MBC_Project) is available in Spanish. Spanish-speaking metastatic breast cancer patients can now enroll in this patient-partnered research initiative. dana-farber.org/newsroom/news-…

We recently spoke with Nikhil Wagle, MD (he/him) about his research on metastatic breast cancer in Black women. Read the wide-ranging interview on our blog. bit.ly/3ysj0f7

"Why is it important that breast cancer research include more Black women? Why have these patients been so understudied?" Nikhil Wagle, MD (he/him) answers this and talks about his new research focused on #MBC in Black women in this The Breast Cancer Research Foundation blog.

Network-based mathematical models contribute to overcoming the challenge of cancer #DrugResistance. Tejeda Zañudo et al develop a model to identify drug combinations with PI3Kα inhibitors for ER+ PIK3CA mutant breast cancer. bit.ly/3kJwO1b Jorge Gómez Tejeda Zañudo @nikhilwagle

The Metastatic Breast Cancer Project (MBCproject.org) has now been fully translated into Spanish, including the wesbsite, consent form, & all project materials — part of our ongoing efforts to make all Count Me In research projects more inclusive & representative

Great teamwork. Thanks Vaciry Adrian Lee @npriedig Vignali Lab Tullia Bruno, PhD JenRicher Ben Ho Park nilguntasdemir Amir Bahreini Kai ding @MCristofanill Jay Gertz Simak Ali Wagle Lab Now the more challenging task - move findings to the clinic! #bcsm